Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction.
Plasma antipyrine half-lives and metabolic clearances were measured after a single oral dose of antipyrine in 10 control subjects, 12 patients with gallstones, and 9 patients having undergone cholecystectomy for cholesterol cholelithiasis, to determine whether impairment of hepatic antipyrine metabolism occurs in patients with cholesterol cholelithiasis. The plasma antipyrine half-life and metabolic clearances in the control subjects were 11.7 plus or minus 1.3 hours and 42.5 plus or minus 3.3 ml/min, respectively; in patients with gallstones, 12.3 plus or minus 1.3 hours and 36.0 plus or minus 3.2 ml/min, respectively; and in patients having undergone cholecystectomy, 13.2 plus or minus 1.8 hours and 33.8 plus or minus 4.2 ml/min, respectively. Values for antipyrine half-life and metabolic clearance were not statistically different in these three groups. This study suggests the presence of normal hepatic antipyrine metablosim in patients with  cholesterolcholelithiasis.
D000328:Adult; D000368:Aged; D000983:Antipyrine / Q000378:metabolism*; D002763:Cholecystectomy; D002769:Cholelithiasis / Q000209:etiology / Q000378:metabolism* / Q000601:surgery; D002784:Cholesterol; D005260:Female; D006207:Half-Life; D006801:Humans; D008099:Liver / Q000378:metabolism; D008297:Male; D008657:Metabolic Clearance Rate; D008862:Microsomes, Liver / Q000378:metabolism*; D008875:Middle Aged
D002784:Cholesterol; D000983:Antipyrine